Next Quarterly Earnings
Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
AbbVie is a global, research-based biopharmaceutical company from the US. It researches, develops, and delivers innovative therapies for some of the world's most complex and serious diseases. Focusing on immunology, oncology, and neuroscience, AbbVie improves patients' lives through scientific innovation and commitment.
Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
AbbVie (ABBV) will release its Q3 2026 earnings before market open on October 30, 2026. Analysts estimate an EPS of 3.84 USD and revenue of 17,312 million USD. In the last reported quarter (Q2 2026), the company reported an EPS of 3.65 USD, beating the estimate of 3.61 USD by 1.2%.
Generated automatically from our data — as of 10/10/2026
AbbVie (ABBV) reported its Q2 2026 financial results on July 31, 2026, before market open. The company reported quarterly earnings per share (EPS) of 3.65 USD, beating the analyst estimate of 3.61 USD by 1.2%. Quarterly revenue reached 16990 million USD. Following the publication, the stock price fell by 2.51%.
Generated automatically from our data — as of 08/06/2026 Read the article →
AbbVie is scheduled to report its next quarterly earnings on 10/30/2026. Pre-market — typically before 3:30 p.m. German time (before the US open at 9:30 a.m. New York time).
AbbVie last reported quarterly earnings on 7/31/2026 (Q2 2026). Earnings per share (EPS) came in at 3.65 USD.
Across its last 5 earnings reports, AbbVie stock moved by ±3.7% on average the following day. The largest reaction was +4.7% on 01/31/2025; 2 of 5 reactions were positive.
AbbVie has beaten analyst EPS estimates in 5 of its last 5 evaluated quarters (beat rate: 100%).
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
Basis: price reactions to the last 5 report dates (close to close).
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.